WO1995026738A1 - Utilisation des polymeres protegeant des facteurs de croissance pour le traitement de l'inflammation - Google Patents
Utilisation des polymeres protegeant des facteurs de croissance pour le traitement de l'inflammation Download PDFInfo
- Publication number
- WO1995026738A1 WO1995026738A1 PCT/FR1995/000400 FR9500400W WO9526738A1 WO 1995026738 A1 WO1995026738 A1 WO 1995026738A1 FR 9500400 W FR9500400 W FR 9500400W WO 9526738 A1 WO9526738 A1 WO 9526738A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- use according
- polymer
- cmdbs
- polysaccharide
- fgf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of polymers or biopolymers for the preparation of a medicament for the treatment of inflammation.
- Inflammation is a particularly complex manifestation that develops after a spontaneous or traumatic tissue injury. Characterized by a change in capillary permeability, it is accompanied by an infiltration of blood, molecular and cellular components, which is generally manifested by erythemas and edemas. Numerous chemical mediators are released or activated during this process during which elements of the blood, in particular white blood cells accumulate and release different lytic activities. Many substances are used as anti-inflammatory agents. They can roughly be classified into steroid and non-steroid agents.
- HBGF Heparin Binding Growth Factors
- Sucrose sulfate ester and its aluminum salt sucralfate are products described and used as anti-inflammatory agents (US Patent No. 3,432,489) and in various combinations and pharmaceutical compositions described in a series of patents (US 4,975,281, 4,885 .281, US 5,013,557, US 5,164,379, US 5,196,405, US 5,240,710 and DK 102,488 and DK 505,588).
- a composition containing a combination of heparin and sulodexide which is a mixture of polymers comprising glycosaminoglycans (GAG) has also been studied for its action in the treatment of mild trauma (Dragani et al., 1989, Minerva Medica, 80, n ° 4, 397-403). However, these two compounds have not been tested separately.
- CMDBS Carboxy Methyl Dextran Benzylamine Sulfonate
- Patent FR 2 644 066 describes the use of certain CMDBS associated with FGF for the healing of the skin and the cornea. Experiments were carried out by causing a cutaneous wound using a 6 mm diameter cookie cutter in rats. In this example, the CMDBS associated with FGF 2 provides a clear effect on the speed and quality of skin repair.
- certain polymers defined as belonging to the class of HBGFPP and in particular CMDBS have an effect on the intensity of the inflammatory reaction which they very markedly decrease while by accelerating the repair, regeneration and restoration processes of damaged tissue.
- skin tissues, bone tissues, HBGFPP combine anti-inflammatory effects.
- the subject of the present invention is the use of at least one polymer or of a biopolymer, called HBGFPP, with the exclusion of mesoglycan, specifically protecting the growth factors of the families of FGF and TGF beta from tryptic degradation and n ' not significantly inhibiting coagulation, for the manufacture of a medicament for the treatment of inflammation of various tissues.
- Such a polymer particularly exhibits an anticoagulant activity of less than 50 international units per mg of polymer measured according to Maillet et al (Mol. Immunol, 1988, 25, 915-923).
- it potentiates the FGF in vitro.
- it does not substantially activate the complement system, that is to say that it has an anti-complement activity greater than 0.5 ⁇ g for CH5O (according to Mauzac et al., Biomaterials, 6, 61 -63, 1985).
- polymers is intended to mean any natural, chemically modified or totally synthetic natural substance corresponding to the definition given above.
- said polymer or biopolymer is a polysaccharide which can be composed mainly of glucose residues.
- It may also include glucosamine and / or uronic acid residues, particularly in the form of the glucosamine-uronic acid dimer.
- Particularly preferred polysaccharides are substituted dextrans, glycosaminoglycans optionally associated with a lipid, a peptide or a protide or sulfates of these polymers.
- Such a polymer advantageously has a molecular weight of at least 10 kDa and preferably around 40 kDa.
- the present invention further relates to a pharmaceutical composition containing these polymers.
- the polymers and / or biopolymers can be selected from natural substances which can then be optionally modified by additions of appropriate chemical groups, or else be obtained entirely by synthesis. These natural, semi-synthetic or fully synthetic polymers are then selected on the basis of their capacities to interact specifically with several growth factors, in particular those of the family of FGF and TGF beta. They can also be selected for their ability to protect this or these factors against proteolytic degradations, and to act as inhibitors of protein activities involved in the inflammatory process such as leukocyte elastase, and plasmin for example, and for their activity. anti-coagulant. These polymers are designated by the generic acronym HBGFPP (heparin binding growth factor protectors and promotors). Two prototypes of these polymers or biopolymers are given as examples as well as the methods and criteria for the selection of these polymers.
- HBGFPP heparin binding growth factor protectors and promotors
- HBGFPP belongs to the family of CMDBS which are known products, namely functionalized biospecific dextrans, substituted with carboxymethyl, benzylamide and benzylamine sulfonate residues. These polymers illustrate the production of HBGFPP from natural products (dextrans) subsequently chemically substituted.
- the second example describes the selection of completely natural products such as glycosaminoglycans sulfates purified from tissue extracts.
- treatment means any curative or preventive operation carried out for the prophylaxis or the resorption of inflammations involving in particular protein activities such as leukocyte elastase, plasmin, metalloproteinases in addition to stimulating effects. tissue regeneration and healing.
- HBGFPP HBGFPP
- CMDBS HBGFPP
- the pharmaceutical composition can also be combined with agents such as, for example, antibacterials, antifungals, vitamins or the like, antiseptics, analgesics, agents protecting against solar radiation and other anti-inflammatory agents or all other types of compounds associated for their specific effects and administered in any pharmaceutical dosage form acceptable and compatible with the type of treatment envisaged.
- agents such as, for example, antibacterials, antifungals, vitamins or the like, antiseptics, analgesics, agents protecting against solar radiation and other anti-inflammatory agents or all other types of compounds associated for their specific effects and administered in any pharmaceutical dosage form acceptable and compatible with the type of treatment envisaged.
- such a composition is designed to be directly absorbed orally, deposited on the lesion or injected if the latter is directly accessible, in particular in subcutaneous, buccal or rectal lesions or even during surgical procedures by depositing or injecting the tissues.
- the unit dose is 10 to 2500 ⁇ g CMDBS or HBGFPP per ml or cm2 of tissue to be treated in a volume adapted to the specificity of the pathology.
- the dose of CMDBS or HBGFP product used corresponds, depending on the area of the wound, to a fraction of a starting solution of 10 to 2,500 ⁇ g per milliliter (which for local application on common wounds rarely involves a deposit greater than a few hundred of microliters of the solution) this dose being applied once or twice per 24 hours.
- compositions used of sucralfate are from 0.01 to 5% (according to US Patent No. 5,196,405) are concentrations at least 10 times greater than those described in the present invention and the effects described in all the examples of this patent US Pat. 196405 are obtained from compositions of 50 milligrams per milliliter.
- the vehicle can be physiological saline or buffers such as PBS containing 0.15 molar NaCl or any other kind of solution which is compatible and not irritating to the injured tissue.
- physiological saline or buffers such as PBS containing 0.15 molar NaCl or any other kind of solution which is compatible and not irritating to the injured tissue.
- the main pathologies associated with an elastase type activity cover the following main areas:
- - skin lesions including the lips, oral cavity, gum (diseases periodontal), mucous membranes for example vaginal and anal surfaces for inflammatory, pruritic, erythematous rashes, acne or rosacea such as seborrhea or pustular inflammation, boils, abscesses;
- otolaryngological and pulmonary sphere such as sinusitis or allergic rhinitis, acute or chronic, otitis, pulmonary inflammatory reactions, edema, emphysema, fibrosis, reactions secondary to bronchitis, asthma;
- diseases linked to immunological or viral disorders such as arthritis and rheumatoid arthritis, synovitis, gout and various forms of arthritis inflammation, lupus erythematosus, anaphylaxis, bacterial septicemia, AIDS;
- parasitic diseases such as toxoplasmosis, cytomegalovirus, malaria, polyomelyte, etc .;
- the main pathologies associated with plasmin-type activities also cover the fields of tumor progression and induced complications.
- Figure 1 shows the formula for CMDBS.
- Figure 2 illustrates the potentiation of the biological activity of FGF1 (2a) and FGF2 (2b) by heparin, mesoglycan and sulodexide.
- the measurement of the biological activity is carried out on CCL39 cells by measuring the increase in the incorporation of tritiated thymidine as a function of the dose of FGF1 and of FGF2 added alone or in the presence of 20 ⁇ g of heparin, 10 ⁇ g of mesoglycan, or
- Figures 3 and 4 illustrate the protective effect of heparin, mesoglycan and sulodexide against thermal degradation of FGF1 (3) and FGF2 (4).
- FGF samples are incubated alone or in the presence of 20 ⁇ g of heparin, 10 ⁇ g of mesoglycan or 10 ⁇ g of sulodexide at 20 ° C (a) and 37 ° C (b) for 1, 7, 15, 30 days.
- the measure of the biological activity presented on the abscissa corresponds to the values of the stimulation units (ED50) for the incorporation of tritiated thymidine in CCL39 cells.
- ED50 stimulation units
- Figure 5a illustrates the protective effect of heparin, mesoglycan and sulodexide against proteolytic degradation of 125 I-FGF1.
- Proteolytic digestion was carried out at 37 "C and the samples were separated by electrophoresis on 18% polyacrylamide gel. The gels are dried and autoradiographs.
- the first lane contains 125 I-FGF1 alone, in the second (lane 2 ) 125 I-FGF1 is incubated in the presence of trypsin and heparin (lane 3), mesoglycan (lane 4) or sulodexide (lane 5).
- Figure 5b illustrates the protective effect of heparin, mesoglycan and sulodexide against proteolytic degradation of 125 I-FGF2.
- the layout of the tracks is identical to that presented for the 125 I-FGF1 in 5a.
- FIGS. 6A and 6B are elution profiles on a DEAE-Trisacryl column respectively from the HSM (FIG. 6A) and HSS (FIG. 6B) fractions, in the presence of chondroitin sulphate (CSA) fractions for the calibration of the column.
- CSA chondroitin sulphate
- FIGS. 7A and 7B respectively represent bone tissues having an inflammation treated with a dressing of collagen soaked in physiological saline (7A), and the same dressing soaked in CMDBS (7B).
- FIGS. 8A to 8C on the one hand and 8D to 8F on the other hand respectively represent sections of skin wounds treated with collagen soaked in CMDBS and collagen soaked in physiological solution.
- CMDBS are dextrans substituted by carboxymethyl, benzylamide and benzylamide sulfonate groups.
- the CMDBS synthesis method can be that described by M.MAUZAC and J.JOSEFONVICZ in
- CMD is prepared from dextran by substitution of a few glycosylated units with carboxylic groups on the carbon in position 5 or
- the benzylamide is coupled to the carboxylic groups to form the carboxymethyl-benzylamide dextran (or CMBD).
- carboxymethyl-benzylamide dextran or CMBD
- some aromatic rings of benzylamide are sulfonated to result in the carboxymethyl dextran benzylamide sulfonate or CMDBS.
- the sodium salts of these derivatives are ultrafiltered, lyophilized and dissolved in the appropriate buffer before use.
- CMDBS have a distribution statistics of the different substituents.
- the percentages for each type of CMDBS are determined by conventional methods,
- CMDBS During the synthesis of CMDBS it is possible to control the rate of substitution of each of the groups by modification of the conditions of the substitution reaction. Control of parameters such as temperature, reaction time, relative concentrations of the constituents and the number of substitution reactions, etc., make it possible to obtain a very large number of substituted polymers.
- the substitution of hydroxyls by carboxymethyl on the carbons in position 5 and 6 makes it possible to obtain carboxymethylation rates ranging from 0 to 200% (100% for each of the carbons in position 5 and 6).
- the carboxymethyl group can in turn be partially or totally used for fixing the benzylamide. Benzylamide groups can be partially or fully used for sulfonation.
- the functionalized substituted dextrans used according to the invention are among those specially described in French patent No. 2,461,724.
- the selected CMDBS In addition to the ability to stabilize and protect the growth factors of the FGF family as described in the publication by Tardieu et al J. Cell.Physio. 1992 150 p 194 to 203; and in French Patent No. 2,461,724; the selected CMDBS must be able to interact with at least one member of the growth factor family of the TGF beta family according to an evaluation method described below and protect the TGF beta against proteolysis.
- ii Evaluation of the interaction capacities between CMDBS and growth factors of the TGF beta family.
- a screening test was established. This test consists in measuring the capacity of the selected CMDBS to allow the TGF beta to keep its biological activity despite a protease treatment.
- the CMDBS used is lot 26.2 defined by a substitution rate of 110% of carboxymethyl units, 3.6% of benzylamide units and 36.5% of sulfonate units and has an anti-coagulant activity of 4 IU / mg (International Units).
- the anti-complement activity of this batch is 1.1 ⁇ g of
- the heparin used as a control comes from Sanofi establishments. (Institut Choay) and has an anticoagulant activity of 175 IU / mg
- TFG beta 1 is prepared from human blood platelets according to the protocol described in numerous publications and commonly used by those skilled in the art, for example in the publication Growth Factors and their Receptors 1992, vol. 1 PP 419-472 by A. Roberts and M.Sporn edited by A. Roberts and M.Sporn and published by Springer Verlag Berlin.
- the test for biological activity of TGF beta used in this example is that of the inhibition of growth of CCL64 cells (from the Ame'ican Tissue Culture Collection).
- TGF beta is used in two doses, one corresponding to the inhibition capacity of 50% of the incorporation of tritiated thymidine (defined as the unit of inhibitory activity) the other, corresponding to the inhibition capacity of 100%.
- the values obtained are 250 ⁇ g of TGF beta to obtain the unit of inhibition activity on CCL64 cells cultured in 1 ml of culture medium. The 100% inhibition is obtained with 1 ng of TGF beta in 1 ml of culture medium.
- a 50 ng sample of TGF beta in phosphate buffered saline containing 0.1% bovine serum albumin is incubated alone, or associated either with 5000 ⁇ g of CMDBS, or with 5000 ⁇ g of heparin , with or without 500 ⁇ g of trypsin.
- the final volume of the incubated solution is adjusted to 1 ml and the incubation is carried out at 37 ° C for a variable time (10 minutes in the example described in Table 1).
- CMDBS had no inhibitory power on the activity of trypsin (tableAU 2).
- 10 ⁇ g of trypsin were incubated either with a substrate (S.87 supplied by the company Serbio, Paris and used according to the recommendations of this supplier) or either with this substrate and a trypsin inhibitor such as that obtained from soybeans ( like the Soyabean trypsin inhibitor or STI from Sigma) these incubations being carried out in the absence or in the presence of variable amounts of CMDBS (lot AM26).
- the enzymatic activity of trypsin was measured by spectrophotometric absorption of the transformation product of S 87 as a function of the incubation time.
- a commercial preparation of proteoglycosaminoglycan and glycosaminoglycans, sulodexide was selected according to its ability to interact with growth factors of the FGF family as well as with those of the beta TGF family.
- Heparan sulfate preparations obtained by fractionation of mesoglycan and sulodexide were also tested.
- the cells used in this example are CCL39 cells which come from the American Tissue Culture Collection.
- the culture conditions and tests for measuring the biological activity of the FGFs are the same as those described in the publication Tardieu et al J. Cell.Physiol. 1992.
- the FGF growth factors used are the recombinant forms FGF1 and FGF 2.
- the FGFl or 2 is used at a dose corresponding to the effective dose (denoted ED50) to induce a stimulation of the biological activity by 50% of the dose inducing the maximum stimulation.
- the biological activity is measured by the capacity to induce an increase in the incorporation of tritiated thymidine in the cells according to the protocols widely described in numerous publications including that of Tardieu et al mentioned previously and also in French patent N ° 2 644,066.
- 1 ⁇ D50 is 5 ng / ml for FGFl and 3 ng / ml for FGF 2, values measured experimentally (Figs.2a and 2b).
- the same stimulation experiment according to the dose of FGF is carried out in the presence of 10 ⁇ g / ml of Sulodexide or 20 ⁇ g / ml of Heparin.
- Figure 2 shows that under these conditions 1 ⁇ D50 becomes 0.4 ng / ml and 0.2 ng / ml respectively for FGF1 and FGF2 in the presence of these doses of Sulodexide or Heparin.
- HBGFPP protect the FGFs against thermal degradations as well as against the inactivation induced by the proteolytic action of trypsin. (Figs. 4 and 5). Likewise, these HBGFPPs protect FGF1 and 2 against inactivation induced by the proteolytic activity of trypsin (Figs. 5a and 5b).
- dextran sulfate Sigma Chemical, of molecular weight 40,000, the dextran used for the synthesis of CMDBS (also from Sigma) of sucrase or sucrose octasulfate (supplied by D. Bar Shalom, Company BUKH MEDIC, in Denmark)
- sucrase is given in US Patent No. 5202311 or dextran sulfate is given in Japanese Patent No. 138 907/88).
- Dextran is the one used for the synthesis of CMDBS AM26.
- the experiment for protecting the biological activity of TGFbeta was carried out in the same way as with the CMDBS as described in Example 1 ii.
- the incubation mixture contains 50 ng of TGF beta (in 0.1% bovine serum albumin) and trypsin (500 ⁇ g).
- Mesoglycan or Sulodexide or dextran sulfate or dextran or sucrase are used at a dose of 5000 ⁇ g.
- TGFbeta The biological activity of TGFbeta is measured as described above after a dilution of 50 times and using CCL64 cells.
- CMDBS capable of meeting the two selection criteria with respect to FGF and TGFbeta
- sulodexide has significant protective activity for TGFbeta.
- Sulodexide and Mesoglycan correspond to mixtures of several substances, most of which consist of different glycosaminoglycans (GAG).
- This purification was obtained by subjecting these solubilized products to an ion exchange chromatography (DEAE - Trisacryl) to remove all the protein contaminants.
- the total GAGs were then purified by eluting the DEAE gel with a sodium acetate solution, pH 4, containing 1.5 M NaCl.
- each GAG product was digested with chondroitinase ABC overnight at 37 ° C (1 unit per mg of GAG). This enzyme degrades all GAGs except for heparan sulfates (HS).
- the digestion products were subjected to chromatography on a molecular sieve (G50 Sephadex, column 1.8 ⁇ 95 cm). The elution is then carried out in ammonium bicarbonate buffer at a flow rate of 18 ml / h. Undigested material that corresponds to HS GAGs is collected in the dead elution volume of the column.
- the GAG concentrations are calculated from their uronic acid content by the carbazole method (Bitter T. and Muir H.M., 1962, Anal. Biochem 4, 330-334).
- HS fractions of each of these two products were chromatographed again on a DEAE Trisacryl gel.
- 1 mg of each HS fraction, purified from mesoglycan (Fig. 6A) or sulodexide (Fig. 6B), in 3 ml was placed on a column equilibrated with 0.05 M NaCl, 0.05 M TMS buffer -Hel pH 7.5.
- the material fixed to the column is desorbed by a salt gradient ranging from 0.05 M NaCI to 1.5 M NaCI in the same acetate buffer.
- 1 ml of each fraction collected was assayed by the carbazole method.
- the material corresponding to the HS constituents of each of the original products has approximately the same elution profile and therefore approximately the same apparent charge. This maximum of the elution peak is obtained for a salt concentration of 0.94 M NaCl.
- a defined fraction of chondroitin sulfate (CSA) was subjected to the same protocol in order to calibrate the chromatography. This CSA fraction which contains only one sulfate group per disaccharide is eluted at an ionic strength of 0.72 M NaCI.
- the HS fraction contains more sulfate groups than the reference CSAs.
- the HS fraction has about two sulfate groups per dissacharidic unit.
- the purified leukocyte elastase was obtained by Elastin Products Co (Owenville, MO, USA) and the plasmin at SIGMA.
- the inhibition of enzymatic activities by these different compounds is carried out at 37oC in a thermostatically controlled bath.
- the enzymes considered are dissolved in a 100 mM Tris-HCL buffer, pH8 for the elastase and pH 7.4 for plasmin, in the presence of 0.02% sodium azide and 0.01% Triton X100 for plasmin.
- the concentrations of substrates and those of enzymes. are: 0.10 mM MeO-Suc-Ala-Ala-Pro-Val-pNA (paranitroanilide) for the 8.3 nM elastase and 0.20 mM dVal-Leu-dLys-pNA for the plasmin at 77 nM. For each condition is established the IC50.
- Table 6 gives the results obtained in which the batch AM6 corresponds to a dextran T40 of 40,000 kD.
- Lot EM5 corresponds to a T10 dextran of 10,000 kD.
- the synthetic intermediates are listed according to the abbreviations designated above, indexed with a number which specifies the number of each of the substitution reactions.
- the IC50 values demonstrate that the CMDBS have non-competitive hyperbolic-type inhibitory effects on the activity of leukocyte elastase comparable to those of heparin, one of the best inhibitors of this activity (Ki of the order of 1 nM). CMDBS also exerts, unlike heparin, inhibitory effects on plasmin.
- the two cephalic regions have not been filled and therefore serve as a control while the left and right posterior sides are filled with collagen (microfilar hemostatic collagen (Pangen) from the laboratories of Fournier Dijon, France) or impregnated collagen overnight in a CMDBS solution at 100 ⁇ g / ml. Appropriate hemostasis was performed before suturing the wound. The wounds are closed with nylon suture thread and the operated side is covered with a sterile dressing. The animals were left in convalescence and no postoperative complications were noted. The animals were euthanized on days 3, 4, 8 and during the 12 weeks following the intervention. All animals received identical treatment and served for their own control. After examination macroscopic of the site of the operation, the skulls are decalcified and included in paraffin.
- the operated side was studied under a microscope to be cultured. After the models are decalcified and placed in paraffin, sagittal sections (5 mm thick) of the zones corresponding to the defects thus created were cut out using a microtome and stained with hematoxylin and l eosin. These sections are studied under a microscope and the defects have been magnified 100 times, using a 2.5 ⁇ 2.5 mm grid normalized by 10 divisions of 0.25 mm on each side. These measurements were then reported on a graph to compare the results according to the different groups treated.
- FIGS. 7A and 7B show the difference in the inflammatory reaction observed after 3 weeks in the granulation tissue corresponding to the filling of the bone defect produced experimentally.
- FIG. 7A which corresponds to the dressing of collagen soaked only with physiological saline, the inflammatory reaction is very strong; granulation tissue contains a large number of inflammatory cells and few osteoblastic cells.
- the stomach is removed, opened according to the large curvature and rinsed.
- the mucosal involvement is rated according to the following scale.
- the CMDBS was dissolved in distilled water, the
- the treatments are carried out orally, 1 hour before ethanol and 45 minutes afterwards in a volume of 5ml / kg.
- TLB trinitrobenzene sulfonic acid
- mice Groups of 6 male Sprague Dawley rats, weighing approximately 200 g, are placed in a young water tank 24 hours before the test. On the day of the test, the animals are anesthetized with pentobarbital (30 mg / kg) intraperitoneally. 20 mg of TNB dissolved in 0.25 ml of 50% ethanol are instilled into the colon 6 cm from the anus. The animals are put back in their cage after waking up with unlimited food and drink.
- the animals are sacrificed and the colon is removed. 30 minutes before the sacrifice, 1 ml of Evans Blue is administered by venous route to evaluate the edema accompanying colitis according to the following protocol: The colon is placed in a tube containing 9 ml of formamide. After centrifugation, the supernatant is removed and a spectrometric assay is carried out at 620nm wavelength.
- CMDBS was dissolved in 0.5% carboxymethylcellulose.
- the treatments were carried out intrarectally in a volume of 1 ml / kg, 4 hours before the TNB 1 time per day until the sacrifice of the animal.
- the CMDBS has an anti-inflammatory effect as shown by the count of inflammatory cells revealed by Evans blue staining. 300 ⁇ g of CMDBS per kg halve this coloration (p ⁇ 0.05).
- the rats are anesthetized by intraperitoneal injection of sodium pentobarbital (0.1 ml / 100 g for healthy rats and 0.05 ml / 100 g for diabetic rats).
- sodium pentobarbital 0.1 ml / 100 g for healthy rats and 0.05 ml / 100 g for diabetic rats.
- Three dermo-epidermal skin defects are practiced on either side of the spine using a 6 mm diameter cookie cutter.
- PBS.ia.PBS for 2 hours at room temperature before being placed in each wound.
- OPSITE occlusive dressing
- Rats are placed in individual cages with unlimited food and water. Each experimental condition includes lots of 6 to 10 animals. The scarring process is considered at variable times expressed in days (Dx) after the date of the operation (D0).
- the wounds of healthy rats are treated with collagen dressings soaked in a physiological solution containing or not CMDBS-AM6 at 50 ⁇ g / ml.
- Tissue samples are placed for 24 to 48 hours in an excess of fixative (4% paraformaldehyde, 0.1% glutaraldehyde, 5% sucrose, 100 mM PBS, pH7) then gradually dehydrated before being included in Paraplast Plus (Prolabo). 5 mm sections are made with a paraffin microtome (Reichert-Yung) and stained with Masson trichrome (GABE, 1988).
- fixative 4% paraformaldehyde, 0.1% glutaraldehyde, 5% sucrose, 100 mM PBS, pH7
- Paraplast Plus Prolabo
- 5 mm sections are made with a paraffin microtome (Reichert-Yung) and stained with Masson trichrome (GABE, 1988).
- FIGS. 8A to 8F report this histological study of skin healing on D6 post-operatively (staining of sections with Masson's Trichrome).
- Figures 8A to 8C show the wounds treated with CMDBS (50 ⁇ g / ml) and Figures 8D to 8F show the wounds treated with the vehicle alone. These figures show an inequality in the quality of the granulation tissue. There is a more mature aspect of the scar (Fig.8A, x4) compared to the control (Fig.8D, x4). An enlargement (x25) of the epidermal region shows a reconstitution of the latter in both cases (Fig. 8B and 8E x25).
- the wound treated (Fig. 8C x25) with CMDBS shows the presence of fibroblasts (arrow) which begins to orient and which produce a matrix in a larger quantity than in the wound witness.
- the inflammatory cells in the wounds treated with CMDBS are in a limited number compared to the control (Fig. 8F x25) which shows the persistence of important inflammatory phenomena.
- EXAMPLE 8 Demonstration of the matrix metalloproteinase activities extracted from the skin tissues during healing.
- Skin tissue samples are taken according to the same protocol and the same experimental conditions as those presented in the previous example.
- the wounds of healthy rats are treated with collagen dressings soaked in a physiological solution containing or not CMDBS-AM6 at 50 ⁇ g / ml.
- C The skin taken on D0 is called a control (C).
- Dx The sample taken on day x (Dx) at the same location according to the original contours is called wound (P).
- C and P are always treated at the same time and according to the same protocol.
- Each sample is sprayed for one minute in a liquid nitrogen mill (Bioblock).
- the powder is weighed and mixed in a 100 mM phosphate buffer pH 7.4, 1M NaCl (1 ml per 100 mg of powder).
- the whole is homogenized with Ultra-turax for 30 seconds, left for 1 hour at 4oC then centrifuged at 43700g (Beckman J2-21) at 4 ° C for 30 minutes.
- the volume of the supernatant is measured and then aliquoted before being stored at -80 ° C.
- the pellet, weighed, is stored at -80 ° C.
- the extracts obtained from shredded skin, scar tissue or not are deposited on 10% polyacrylamide gels containing 1 mg / ml of gelatin (Sigma, ref G2500). After migration in Laemmli buffer, the proteins deposited on gels are renated with a 100 mM Tris-HCl solution, pH 7.4 containing 2.5% of triton x100 (2 times 30 minutes). The Triton is removed by two washes in 100 mM Tris-HCl buffer.
- the electrophoresis gels are incubated at 37 ° C for 48 hours in a 100 mM Tris-HCl buffer containing 10 mM CaCl2, 0.001% NaN3, 0.0015% Brij 35, 1 mM ZnCl2. After carefully removing the incubation buffer, the gels are stained for 20 minutes with stirring with a Coomasie R250 solution (5mg / ml) containing acetic acid (10%), propanol-2 (30%), then discolored (acetic acid 10%, methanol 40%), up to '' with visualization of the bands. The gels are photographed.
- the samples are incubated in the presence of specific inhibitors; Phenyl methyl sulfonyl fluoride or PMSF (2 mM final) inhibitor of serine endopeptidases, ethylenediaminetetraacetic acid or EDTA (20 mM final) inhibitor of metalloendopeptidases, N-ethyl maleimide or NEM (2 mM final).
- specific inhibitors Phenyl methyl sulfonyl fluoride or PMSF (2 mM final) inhibitor of serine endopeptidases, ethylenediaminetetraacetic acid or EDTA (20 mM final) inhibitor of metalloendopeptidases, N-ethyl maleimide or NEM (2 mM final).
- FIG. 9 shows the expression of the matrix metalloproteinases detected in the extracts of wounds as a function of the treatment or not with the CMDBS and as a function of the healing time.
- Tracks 1.12 represent healthy skin which serves as an internal witness to migration.
- Lanes 2, 3, 4 and 13, 14, 15 represent the extracts obtained from scars treated with CMDBS at a rate of 50 mg / ml (6 different rats).
- Tracks 5 to 11 and 16, 17 represent the corresponding witnesses. Each track represents a different rat.
- Two types of collagenases are found in healthy skin: The 72 kDa form and its activated form 68 kDa.
- 92 kDa is present identically. The difference is in the expression levels of 72 kDa and its activated form, 68 kDa.
- D5 and D6 in wounds treated or not with CMDBS, 92 kDa is present identically. The difference is in the expression levels of 72 kDa and its activated form, 68 kDa.
- the 72 kDa and the 68 kDA are expressed very significantly compared to the wounds treated with CMDBS.
- this difference is confirmed since for the same protein deposition as on D5, the activity of collagenases is such that lanes 16 and 17 appear in the form of two white traces. This activity which does not exist in rats treated with CMDBS.
- CMDBS therefore modulates the expression levels of MMPs either directly or indirectly through their inhibitory role on plasmin, which is one of their activators.
- HSS Heparans Sulfates purified from Sulodexide TABLE 5
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7525454A JPH10503167A (ja) | 1994-03-30 | 1995-03-29 | 炎症処置用の成長因子保護ポリマーの使用 |
EP95915224A EP0752864A1 (fr) | 1994-03-30 | 1995-03-29 | Utilisation des polymeres protegeant des facteurs de croissance pour le traitement de l'inflammation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9403805A FR2718024B1 (fr) | 1994-03-30 | 1994-03-30 | Médicament et composition pharmaceutique pour le traitement de l'inflammation. |
FR94/03805 | 1994-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995026738A1 true WO1995026738A1 (fr) | 1995-10-12 |
Family
ID=9461616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1995/000400 WO1995026738A1 (fr) | 1994-03-30 | 1995-03-29 | Utilisation des polymeres protegeant des facteurs de croissance pour le traitement de l'inflammation |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0752864A1 (fr) |
JP (1) | JPH10503167A (fr) |
CA (1) | CA2186758A1 (fr) |
FR (1) | FR2718024B1 (fr) |
WO (1) | WO1995026738A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2794649A1 (fr) * | 1999-06-11 | 2000-12-15 | Solutions | Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2781485B1 (fr) | 1998-07-21 | 2003-08-08 | Denis Barritault | Polymeres biocompatibles leur procede de preparation et les compositions les contenant |
FR2781375A1 (fr) * | 1998-07-21 | 2000-01-28 | Denis Barritault | Composition anti-fibrotique contenant des polymeres ou biopolymeres et leurs utilisations |
FR2781374B1 (fr) * | 1998-07-21 | 2001-06-29 | Denis Barritault | Composition antioxydante comprenant au moins un polymere ou biopolymere seul ou associe a la sod |
FR2781376B1 (fr) * | 1998-07-22 | 2001-05-25 | Denis Barritault | Composition protectrice et regulatrice de l'homeostasie de la masse osseuse contenant des polymeres ou biopolymeres et leurs utilisations |
FR2861308A1 (fr) * | 2003-10-28 | 2005-04-29 | Organes Tissus Regeneration Re | Utilisation de polymeres biocompatibles pour la preparation d'une composition pharmaceutique, dermatologique ou cosmetique destinee a la prevention, au soulagement ou au traitement des genes, desagrements et douleurs |
JP5026791B2 (ja) * | 2003-10-28 | 2012-09-19 | オルガンズ ティシューズ リジェネレーション リパレーション レムプレースメント − オーティーアール3 | 医療用化合物あるいは医療用製品を作成するための生体適合性ポリマーの使用方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2461724A1 (fr) * | 1979-07-20 | 1981-02-06 | Christine Fougnot | Polymeres substitues par des groupes leur conferant des proprietes anti-coagulantes et leur procede de preparation, objets constitues par et/ou comprenant lesdits polymeres et leurs procedes de fabrication, application desdits objets en chirurgie et en medecine, et compositions pharmaceutiques contenant lesdits polymeres substitues |
FR2644066A1 (fr) * | 1989-03-09 | 1990-09-14 | Therapeutiques Substitutives | Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques |
-
1994
- 1994-03-30 FR FR9403805A patent/FR2718024B1/fr not_active Expired - Fee Related
-
1995
- 1995-03-29 CA CA002186758A patent/CA2186758A1/fr not_active Abandoned
- 1995-03-29 WO PCT/FR1995/000400 patent/WO1995026738A1/fr not_active Application Discontinuation
- 1995-03-29 EP EP95915224A patent/EP0752864A1/fr not_active Withdrawn
- 1995-03-29 JP JP7525454A patent/JPH10503167A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2461724A1 (fr) * | 1979-07-20 | 1981-02-06 | Christine Fougnot | Polymeres substitues par des groupes leur conferant des proprietes anti-coagulantes et leur procede de preparation, objets constitues par et/ou comprenant lesdits polymeres et leurs procedes de fabrication, application desdits objets en chirurgie et en medecine, et compositions pharmaceutiques contenant lesdits polymeres substitues |
FR2644066A1 (fr) * | 1989-03-09 | 1990-09-14 | Therapeutiques Substitutives | Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques |
Non-Patent Citations (3)
Title |
---|
A. SAGGIORO ET AL.: "Treatment of hemmorhoidal syndrome with mesoglycan sulfate.", MINERVA DIETOL. GASTROENTEROL., vol. 31, no. 2, pages 311 - 315 * |
G. CORBELLI ET AL.: "Evaluation of the stability of vessel, a glycosaminoglycan sulfate of extractive origin, and heparin in human digestive juices.", BOLL. CHIM. FARM., vol. 119, no. 8, pages 487 - 498 * |
L. DRAGANI ET AL.: "A heparin-glucuronilglucoasminoglycan for topical use.", MINERVA MED., vol. 80, no. 4, pages 397 - 403 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2794649A1 (fr) * | 1999-06-11 | 2000-12-15 | Solutions | Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications |
WO2000076562A1 (fr) * | 1999-06-11 | 2000-12-21 | Biodex | Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance |
Also Published As
Publication number | Publication date |
---|---|
JPH10503167A (ja) | 1998-03-24 |
EP0752864A1 (fr) | 1997-01-15 |
CA2186758A1 (fr) | 1995-10-12 |
FR2718024B1 (fr) | 1996-06-21 |
FR2718024A1 (fr) | 1995-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0752863B1 (fr) | Utilisation de biopolymeres pour le traitement de lesions du tractus digestif | |
EP1940448B1 (fr) | Complexe polymere amphiphile-pdgf | |
Basavaraj et al. | The role of urinary kidney stone inhibitors and promoters in the pathogenesis of calcium containing renal stones | |
EP1117695B1 (fr) | Polymeres biocompatibles, les compositions les contenant et leur utilisation pour la préparation de médicaments | |
US20110124596A1 (en) | Composition for treating inflammatory diseases | |
JPH11513990A (ja) | 鮫軟骨エキス | |
CH672886A5 (fr) | ||
LU85582A1 (fr) | Fractions d'acide hyaluronique ayant une activite pharmaceutique,procedes pour leur preparation et compositions pharmaceutiques les contenant | |
WO1995026738A1 (fr) | Utilisation des polymeres protegeant des facteurs de croissance pour le traitement de l'inflammation | |
EP0752862B1 (fr) | Utilisation de biopolymeres pour le traitement des muscles | |
EP1406637B1 (fr) | Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane | |
FR2861308A1 (fr) | Utilisation de polymeres biocompatibles pour la preparation d'une composition pharmaceutique, dermatologique ou cosmetique destinee a la prevention, au soulagement ou au traitement des genes, desagrements et douleurs | |
BRPI0720874B1 (pt) | composições compreendendo peptídeos bioativos curtos para modulação celular e imunológica | |
EP0752865B1 (fr) | Utilisation de dextrane substitue pour le traitement des lesions du systeme nerveux et fractions enrichies en herapane sulfate | |
EP0063973B2 (fr) | Composition pour collyre à base de sulfate de chondroitine A | |
JPH06312941A (ja) | Hgf産生促進剤 | |
EP2714706A1 (fr) | Sucroses octasulfates de calcium, leur préparation et leurs applications pharmaceutiques et cosmétiques | |
EP0233459A1 (fr) | Médicament contenant un complexe acétylsalicylate de magnésium-urée et procédé pour la fabrication de ce complexe | |
WO2008120085A2 (fr) | Composition angiogenique comprenant un complexe entre un polymere amphiphile et un pdgf | |
JPS63152328A (ja) | 酵素阻害剤 | |
WO2009004152A2 (fr) | Utilisation d'une composition d'oligomères d'acide galacturonique en tant qu'agent pour inhiber la dégradation du collagène | |
WO2008120264A1 (fr) | Utilisation de misoprostol pour le traitement topique de lésions de la peau par des dards et des brûlures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995915224 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2186758 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1997 714179 Country of ref document: US Date of ref document: 19970106 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1995915224 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995915224 Country of ref document: EP |